Medicare on Thursday announced plans for coverage of new Alzheimer’s drugs whose accessibility has become a point of controversy.
For drugs that are granted traditional Food and Drug Administration approval, Medicare will provide coverage for beneficiaries with an appropriate diagnosis and a qualified doctor participating in collection of real-world evidence on how the drugs are working — a system known as a registry, the Centers for Medicare and Medicaid Services said.
“CMS…
Read the full article here
